stockrow
Friday 6 November 2026
Export VMD’s income statement to Excel — free account
Viemed Healthcare, Inc.
VMD Healthcare Medical Devices
Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024.
- Revenue
- +12.2%
- EPS
- +38.1%
- Free cash flow
- −67.6%
- Total debt
- −62.8%
Quarter to September 2026, against a year earlier
9.18
0.17
+1.89%
Follow VMD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
19.05 | 23.62 | 30.00 | 21.96 |
P/S ratio |
1.07 | 1.24 | 1.45 | 1.12 | |
P/FCF ratio |
16.75 | 13.87 | 18.47 | 22.77 | |
P/Operating CF |
0.00 | 43.85 | 27.42 | 30.18 | |
P/B ratio |
2.01 | 2.43 | 2.99 | 2.28 | |
Price to Tangible BV |
3.47 | 4.13 | 5.08 | 3.77 | |
EV/Sales |
1.07 | 1.23 | 1.43 | 1.11 | |
EV/EBITDA |
6.97 | 7.70 | 9.17 | 7.10 | |
EV/Operating CF |
8.67 | 9.13 | 10.21 | 9.73 | |
EV/FCF |
16.82 | 13.85 | 18.32 | 22.65 | |
Quick Ratio |
0.96 | 1.01 | 0.90 | 0.94 | |
Current Ratio |
1.18 | 1.22 | 1.13 | 1.25 | |
Net Debt/EBITDA |
0.14 | (0.05) | (0.29) | (0.12) | |
Debt/Assets |
7.40% | 4.66% | 3.47% | 3.78% | |
Debt/Equity |
0.10 | 0.06 | 0.05 | 0.05 | |
Asset Turnover |
1.44 | 1.53 | 1.55 | 1.51 | |
Operating CF/Net income |
0.00 | 3.13 | 5.75 | 2.48 | |
Capex/Depreciation |
0.00 | (0.71) | (0.96) | (0.96) | |
Interest Coverage |
23.62 | 15.14 | 20.13 | 41.33 | |
Research and Development Expense of Revenue |
0.78% | 0.77% | 0.65% | 0.62% | |
Selling, General and Administrative Expense of Revenue |
45.31% | 49.38% | 50.15% | 47.08% | |
Intangible Assets out of Total Assets |
0.30 | 0.30 | 0.29 | 0.29 | |
Share Based Compensation of Revenue |
0.00% | 3.25% | 2.60% | 3.07% | |
Graham Net Nets |
(0.02) | 0.00 | (0.01) | 0.01 | |
Graham Number |
5.69 | 5.77 | 5.71 | 6.10 | |
Earnings Yield |
5.25% | 4.23% | 3.33% | 4.55% | |
Free Cash Flow Yield |
5.97% | 7.21% | 5.41% | 4.39% | |
Revenue per Share |
1.96 | 1.96 | 2.04 | 2.12 | |
Operating CF per Share |
0.00 | 0.21 | 0.42 | 0.30 | |
Capex per Share |
0.00 | (0.14) | (0.19) | (0.20) | |
Free Cash Flow per Share |
0.00 | 0.07 | 0.23 | 0.11 | |
Cash per Share |
0.35 | 0.25 | 0.28 | 0.25 | |
Shareholders Equity per Share |
3.69 | 3.79 | 3.82 | 3.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.69 | 3.79 | 3.82 | 3.99 | |
Free Cash Flow |
0.00 | 2.59 | 8.62 | 4.03 | |
Working Capital |
7.44 | 9.11 | 6.07 | 11.97 | |
Capital Expenditures |
0.00 | (5.48) | (7.29) | (7.46) | |
Net Current Asset Value |
(7.14) | (1.75) | (4.29) | 3.64 | |
EV/EBIT |
14.19 | 14.92 | 17.81 | 13.51 | |
Capex to Sales |
0.00 | 0.07 | 0.09 | 0.09 | |
Price to Operating Income |
14.13 | 14.95 | 17.96 | 13.59 | |
| Other line items | |||||
Average Receivables |
25.36 | 28.98 | 29.39 | 32.11 | |
Average Payables |
6.33 | 8.26 | 9.62 | 9.65 | |
Average Inventory |
4.68 | 4.85 | 4.80 | 4.91 | |
Average Assets |
188.11 | 187.72 | 194.41 | 205.00 | |
Average Common Equity |
138.41 | 141.27 | 143.79 | 143.74 |
Columns are period end dates · fundamentals updated 6 Nov 2026